Hatteras Venture Partners related stories
All articles and analysis
Hatteras Venture Partners Has $74 Mln First Close for Fourth FundHatteras Venture Partners announced the first close of its fourth fund with $74 million in subscriptions. The final target for HVP IV is $125 million. Hatteras, of Durham, N.C., invests in seed stage companies and projects in the field of human medicine and life sciences.
- PhaseBio Pharma Adds $15M in Series B Financing
PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.
- Week in deals, Aug. 16, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- TetraLogic Pharma Raises $32 Million
TetraLogic Pharmaceuticals, a Malvern, Penn.-based developer of small molecule drugs to treat cancer, has raised $32 million in Series C funding. Clarus Ventures led the round, and was joined by Hatteras Venture Partners and return backers Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group.
- peHUB Wire: Wednesday, August 11, 2010
Story Time
- peHUB Wire: Wednesday, August 11, 2010
Story Time
- Exit watch, week of March 1, 2010
News reports about BitBand and other investment-backed companies bought in the past week
- peHUB Wire: Tuesday, February 23, 2010
Random Ramblings
- peHUB Wire: Tuesday, February 23, 2010
Random Ramblings
- Viamet Pharma Signs Option Deal with Novartis
Viamet Pharmaceuticals Inc., a Morrisville, N.C.-based biotech company targeting metalloenzymes, has signed a licensing option agreement with Novartis Option Fund. The deal could be worth upwards of $200 million, including an up-front payment and earnouts. Viamet previously raised around $24 million in VC funding, from Novartis Option Fund, Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.